Main menu

Pharmacogenomic biomarkers for improved drug therapy - recent progress and future developments


This paper aimed to provide an overview of recent advancements in pharmacogenomic biomarkers, which are critical in predicting individual drug responses and reducing adverse drug reactions (ADRs). The review discusses the role of genetic polymorphisms in drug-metabolizing enzymes, particularly cytochrome P450 enzymes, and highlights the importance of rare genetic variants in pharmacogenomics.

It also addresses the challenges of implementing pharmacogenomic biomarkers in clinical practice, emphasizing the need for personalised medicine, especially in oncology.

The authors discussed emerging technologies that facilitate biomarker discovery, including long-read sequencing platforms such as those developed by Oxford Nanopore Technologies (ONT). This technology was highlighted for its potential to overcome challenges associated with short-read sequencing, such as accurately detecting structural variants, copy number variations (CNVs), and repetitive elements, which are important for pharmacogenomic analysis.

Technologies producing long reads enable more comprehensive analysis of complex regions of the genome, such as those found in cytochrome P450 genes, which are critical for drug metabolism.

Authors: Volker M. Lauschke, Lili Milani, Magnus Ingelman-Sundberg

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

纳米孔技术

订阅 Nanopore 更新 资源库及发表刊物 什么是 Nanopore 社区

关于 Oxford Nanopore

新闻 公司历程 可持续发展 领导团队 媒体资源和联系方式 投资者 合作者 在 Oxford Nanopore 工作 职位空缺 商业信息 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag